MED Device.jpg

Innovio creates HIV Breakthrough

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.


Read more: http://www.nasdaq.com/press-release/inovio-hiv-vaccine-elicits-nearly-100-immune-response-rates-in-a-clinical-study-20170524-00496#ixzz4igA1xNT9